215 related articles for article (PubMed ID: 22425607)
41. Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III Trial.
Gogas H; Dafni U; Karina M; Papadimitriou C; Batistatou A; Bobos M; Kalofonos HP; Eleftheraki AG; Timotheadou E; Bafaloukos D; Christodoulou C; Markopoulos C; Briasoulis E; Papakostas P; Samantas E; Kosmidis P; Stathopoulos GP; Karanikiotis C; Pectasides D; Dimopoulos MA; Fountzilas G
Breast Cancer Res Treat; 2012 Apr; 132(2):609-19. PubMed ID: 22187126
[TBL] [Abstract][Full Text] [Related]
42. Pathologic complete response as a potential surrogate for the clinical outcome in patients with breast cancer after neoadjuvant therapy: a meta-regression of 29 randomized prospective studies.
Berruti A; Amoroso V; Gallo F; Bertaglia V; Simoncini E; Pedersini R; Ferrari L; Bottini A; Bruzzi P; Sormani MP
J Clin Oncol; 2014 Dec; 32(34):3883-91. PubMed ID: 25349292
[TBL] [Abstract][Full Text] [Related]
43. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial.
Trimbos JB; Vergote I; Bolis G; Vermorken JB; Mangioni C; Madronal C; Franchi M; Tateo S; Zanetta G; Scarfone G; Giurgea L; Timmers P; Coens C; Pecorelli S;
J Natl Cancer Inst; 2003 Jan; 95(2):113-25. PubMed ID: 12529344
[TBL] [Abstract][Full Text] [Related]
44. Final 10-year results of the Breast International Group 2-98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer.
Sonnenblick A; Francis PA; Azim HA; de Azambuja E; Nordenskjöld B; Gutiérez J; Quinaux E; Mastropasqua MG; Ameye L; Anderson M; Lluch A; Gnant M; Goldhirsch A; Di Leo A; Barnadas A; Cortes-Funes H; Piccart M; Crown J
Eur J Cancer; 2015 Aug; 51(12):1481-9. PubMed ID: 26074397
[TBL] [Abstract][Full Text] [Related]
45. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741.
Citron ML; Berry DA; Cirrincione C; Hudis C; Winer EP; Gradishar WJ; Davidson NE; Martino S; Livingston R; Ingle JN; Perez EA; Carpenter J; Hurd D; Holland JF; Smith BL; Sartor CI; Leung EH; Abrams J; Schilsky RL; Muss HB; Norton L
J Clin Oncol; 2003 Apr; 21(8):1431-9. PubMed ID: 12668651
[TBL] [Abstract][Full Text] [Related]
46. German adjuvant intergroup node-positive study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer.
von Minckwitz G; Möbus V; Schneeweiss A; Huober J; Thomssen C; Untch M; Jackisch C; Diel IJ; Elling D; Conrad B; Kreienberg R; Müller V; Lück HJ; Bauerfeind I; Clemens M; Schmidt M; Noeding S; Forstbauer H; Barinoff J; Belau A; Nekljudova V; Harbeck N; Loibl S
J Clin Oncol; 2013 Oct; 31(28):3531-9. PubMed ID: 23980081
[TBL] [Abstract][Full Text] [Related]
47. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial.
Francis P; Crown J; Di Leo A; Buyse M; Balil A; Andersson M; Nordenskjöld B; Lang I; Jakesz R; Vorobiof D; Gutiérrez J; van Hazel G; Dolci S; Jamin S; Bendahmane B; Gelber RD; Goldhirsch A; Castiglione-Gertsch M; Piccart-Gebhart M;
J Natl Cancer Inst; 2008 Jan; 100(2):121-33. PubMed ID: 18182617
[TBL] [Abstract][Full Text] [Related]
48. Adjuvant taxane-based chemotherapy for early stage breast cancer: a real-world comparison of chemotherapy regimens in Ontario.
Torres S; Trudeau M; Eisen A; Earle CC; Chan KKW
Breast Cancer Res Treat; 2015 Jul; 152(1):137-145. PubMed ID: 26026467
[TBL] [Abstract][Full Text] [Related]
49. Efficacy of bevacizumab (Bev) plus chemotherapy (CT) compared to CT alone in previously untreated locally advanced or metastatic non-small cell lung cancer (NSCLC): systematic review and meta-analysis.
Botrel TE; Clark O; Clark L; Paladini L; Faleiros E; Pegoretti B
Lung Cancer; 2011 Oct; 74(1):89-97. PubMed ID: 21377753
[TBL] [Abstract][Full Text] [Related]
50. Evolving treatment approaches for early breast cancer.
Campos SM
Breast Cancer Res Treat; 2005; 89 Suppl 1():S1-7. PubMed ID: 15770534
[TBL] [Abstract][Full Text] [Related]
51. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses.
Baum M; Buzdar A; Cuzick J; Forbes J; Houghton J; Howell A; Sahmoud T;
Cancer; 2003 Nov; 98(9):1802-10. PubMed ID: 14584060
[TBL] [Abstract][Full Text] [Related]
52. Effects of capecitabine as part of neo-/adjuvant chemotherapy - A meta-analysis of individual breast cancer patient data from 13 randomised trials including 15,993 patients.
van Mackelenbergh MT; Seither F; Möbus V; O'Shaughnessy J; Martin M; Joensuu H; Untch M; Nitz U; Steger GG; Miralles JJ; Barrios CH; Toi M; Bear HD; Muss H; Reimer T; Nekljudova V; Loibl S
Eur J Cancer; 2022 May; 166():185-201. PubMed ID: 35305453
[TBL] [Abstract][Full Text] [Related]
53. Dose-dense adjuvant chemotherapy for node-positive breast cancer in women 60 years and older: feasibility and tolerability in a subset of patients in a randomized trial.
Kümmel S; Krocker J; Kohls A; Breitbach GP; Morack G; Budner M; Blohmer JU; Lichtenegger W; Elling D
Crit Rev Oncol Hematol; 2006 May; 58(2):166-75. PubMed ID: 16387512
[TBL] [Abstract][Full Text] [Related]
54. Dose-dense adjuvant chemotherapy: a systematic review and meta-analysis of the Japanese Breast Cancer Society Clinical Practice Guideline, 2018 edition.
Yoshinami T; Koizumi K; Nagai SE; Toyama T; Iwata H
Breast Cancer; 2020 May; 27(3):334-339. PubMed ID: 31916188
[TBL] [Abstract][Full Text] [Related]
55. International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma.
Trimbos JB; Parmar M; Vergote I; Guthrie D; Bolis G; Colombo N; Vermorken JB; Torri V; Mangioni C; Pecorelli S; Lissoni A; Swart AM; ;
J Natl Cancer Inst; 2003 Jan; 95(2):105-12. PubMed ID: 12529343
[TBL] [Abstract][Full Text] [Related]
56. Comparative Effectiveness of Adjuvant Chemotherapy in Early-Stage Breast Cancer: A Network Meta-analysis.
John P; Osani MC; Kodali A; Buchsbaum R; Bannuru RR; Erban JK
Clin Breast Cancer; 2021 Feb; 21(1):e22-e37. PubMed ID: 32917538
[TBL] [Abstract][Full Text] [Related]
57. Multitargeted antiangiogenic tyrosine kinase inhibitors combined to chemotherapy in metastatic breast cancer: a systematic review and meta-analysis.
Wang Z; Wang M; Yang F; Nie W; Chen F; Xu J; Guan X
Eur J Clin Pharmacol; 2014 May; 70(5):531-8. PubMed ID: 24562632
[TBL] [Abstract][Full Text] [Related]
58. Does dose-dense neoadjuvant chemotherapy have clinically significant prognostic value in breast cancer?: A meta-analysis of 3,724 patients.
Ding Y; Ding K; Yang H; He X; Mo W; Ding X
PLoS One; 2020; 15(5):e0234058. PubMed ID: 32470093
[TBL] [Abstract][Full Text] [Related]
59. Bisphosphonates in the adjuvant setting of breast cancer therapy--effect on survival: a systematic review and meta-analysis.
Ben-Aharon I; Vidal L; Rizel S; Yerushalmi R; Shpilberg O; Sulkes A; Stemmer SM
PLoS One; 2013; 8(8):e70044. PubMed ID: 23990894
[TBL] [Abstract][Full Text] [Related]
60. Combination or single-agent chemotherapy as adjuvant treatment of gastric cancer: A systematic review and meta-analysis of published trials.
Iacovelli R; Pietrantonio F; Maggi C; de Braud F; Di Bartolomeo M
Crit Rev Oncol Hematol; 2016 Feb; 98():24-8. PubMed ID: 26481953
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
